Cell: The antibody can prevent severe neo-coronary pneumonia

December 18, 2020 /--- Understanding the body's immune response to the SARS-CoV-2 virus that causes neo-coronary pneumonia (COVID-19) is key to the development of effective drugs and long-lasting vaccines.
particularly noteworthy are the bodies that prevent the virus from entering and infecting human cells, helping the immune system to remove the virus and prevent future infections.
now, in a new study, researchers from the Lagan Institute in the United States and Massachusetts General Hospital have found that the effectiveness of the meso-antibodies produced in patients with severe or fatal diseases is significantly reduced compared to those with lighter infections.
results were published online December 15, 2020 in the journal Cell under the title "COVID-19 neutralizing anti-bodies predict disease and survival".
a transmission mirror image of SARS-CoV-2 (previously known as 2019-nCoV) from NIAID RML.
and antibodies are associated with positive clinical outcomes," said Dr. Alejandro Balazs, author of the paper and a core member of the Lagan Institute.
found that if patients produced more effective antibodies to the virus, they seemed to have better clinical outcomes.
" Balazs and his team have developed an automated test that measures the effectiveness of antibodies in hundreds of COVID-19 patient samples at a time.
they used the technique to examine samples from 113 COVID-19 patients and compare lighter cases with larger or fatal cases to understand the nuances of the antibody response.
found that the effectiveness of the meso-antibodies in severe or fatal COVID-19 patients was significantly lower than in patients with mild illness.
, they built a model that showed that measuring the effectiveness of these meso-antibodies could predict clinical outcomes in patients. "By measuring the mesothetic effects of antibodies in patients, we may be able to identify patients at risk of serious illness or death as a way to guide treatment options," said dr. Wilfredo Garcia-Beltran of Massachusetts General Hospital, co-author of the
paper.
" these mediated antibodies are also effective against the recently discovered widely discovered SARS-CoV-2 variant of the D614G mutation, suggesting that the antibody response produced in most patients may provide protection, even if the virus mutates.
However, by modifying their test methods to observe the meso effects of a similar coronavirus found in bats, they found that the resulting antibody response was largely ineffective, suggesting that the coronavirus strain could pose a threat if transmitted to humans. "While the ability to prevent mutant forms of the virus is promising, these findings suggest that in order to respond to possible future pandemics, we need to focus on developing vaccines that provide a broad protective response," said Evan Lam of the Lagan Institute, co-lead author of the
paper.
" (Bioon.com) Reference: 1. Wilfredo F. Garcia-Beltran et al. COVID-19 neutralizing antibodies predict disease severity and survival. Cell, 2020, doi:10.1016/j.cell.2020.12.015.2.Neutralizing antibodies protect against severe COVID-19。